Giannuzzi Federico, Carlà Matteo Mario, Crincoli Emanuele, Gambini Gloria, Hu Lorenzo, Boselli Francesco, Cuffaro Giovanni, Parrilla Claudio, Rigante Mario, Pagliara Monica Maria, Rizzo Stanislao, Savino Gustavo
Ophthalmology Unit, "Fondazione Policlinico Universitario A. Gemelli, IRCCS", 00168, Rome, Italy.
Catholic University "Sacro Cuore", Largo A. Gemelli, 8, 00168, Rome, Italy.
Int Ophthalmol. 2025 May 3;45(1):160. doi: 10.1007/s10792-025-03535-0.
The aim of our review is to report the thyroid orbitopathy treatments, focusing on novel medicines and ongoing research.
Review developed by a research group at Catholic University of the Sacred Heart.
Overview of the literature synthesizing the findings of literature retrieved from searches of computerized databases, hand searches and authoritative texts. Although minimally invasive surgical techniques have been developed, current research is placing greater emphasis on the use of biological and immunosuppressive drugs for the treatment of thyroid eye disease (TED). Teprotumumab, a monoclonal antibody targeting the insulin-like growth factor-1 receptor, has just been approved by the Food and Drug Administration as a therapy for the treatment of TED. This approval is based on its ability to relieve both the clinical signs and symptoms of the condition, such as proptosis and diplopia. Synthetic peptides imitating T cell epitopes and TSHR-CAR-T cells represent a potential and novel immunotherapeutic strategy.
The growth of several novel therapies highlights the intricate nature of the disease's aetiology and the multitude of processes involved in its regulation. These advancements reveal a future direction focused on personalized treatment of Graves' orbitopathy. The integration of multiple disciplines is becoming increasingly indispensable in the management of patients with this disease.
我们综述的目的是报告甲状腺眼病的治疗方法，重点关注新型药物和正在进行的研究。
由圣心天主教大学的一个研究小组开展的综述。
对从计算机数据库检索、手工检索和权威文献中获取的文献研究结果进行文献综述。尽管已经开发出了微创手术技术，但目前的研究更侧重于使用生物药物和免疫抑制药物来治疗甲状腺眼病（TED）。替普罗单抗，一种靶向胰岛素样生长因子-1受体的单克隆抗体，刚刚被美国食品药品监督管理局批准用于治疗TED。这一批准是基于其缓解该疾病临床体征和症状（如眼球突出和复视）的能力。模仿T细胞表位的合成肽和促甲状腺激素受体嵌合抗原受体T细胞代表了一种潜在的新型免疫治疗策略。
几种新型疗法的发展凸显了该疾病病因的复杂性以及其调节过程的多样性。这些进展揭示了未来针对格雷夫斯眼眶病个性化治疗的方向。在该疾病患者的管理中，多学科整合正变得越来越不可或缺。
